Abstract: An inductor including an element body containing metal magnetic powder and resin and having a coil conductor that has a winding portion, an extended portion extended from the winding portion, and an outer electrode connection portion leading to the extended portion and connected to an outer electrode and is embedded in the element body; and an element body coat covering a surface of the element body. The outer electrode is formed on a surface of the element body and connected to the outer electrode connection portion, in which the outer electrode connection portion has a region covered with the element body coat and a region connected to the outer electrode on the surface of the element body.

Abstract: The present invention provides a novel compound having an excellent antitumor effect stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: A production method for a genetically modified megakaryocyte, the method including a step of introducing a CRISPR-associated (Cas) family protein and guide RNA (gRNA) into a megakaryocyte to modify a subject gene, in which the Cas family protein and the gRNA to be introduced into the megakaryocyte in the step form a complex beforehand. This production method is useful as a technique for producing a genetically modified megakaryocyte and a modified platelet.

Abstract: The invention is directed to a method for determining condition parameters for photodynamic therapy in which after administration of 5-aminolevulinic acids, protoporphyrin IX accumulated in cells is irradiated with light, the method including steps of: calculating, in an experimental phase, a regression curve representing a correlation among three condition parameters: cell viability (Y), intracellular protoporphyrin IX accumulation (X), and light irradiation energy density (P); and selecting in advance, prior to initiation of therapy, two condition parameters from the cell viability (Y), the intracellular protoporphyrin IX accumulation (X), and the light irradiation energy density (P), and then determining the remaining condition parameter using the regression curve. Thus, the photodynamic therapy can be optimized.

Abstract: Provided are a pharmaceutical composition for treating or preventing drug-resistant cancer by photodynamic therapy (PDT) that contains 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of these, and a method for treating or preventing drug-resistant cancer using the pharmaceutical composition.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or it lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: A station includes a reservation request transmitter, a bandwidth request transmitter, and a data transmitter. The reservation request transmitter transmits a reservation request to an access point during a contention slot specified by the access point. The contention slot is periodically allocated by the access point. The bandwidth request transmitter transmits a bandwidth request to the access point using a first allocated bandwidth allocated to the station as a response to the reservation request. The bandwidth request has a first data structure different from a second data structure of the reservation request, and includes information indicating a required bandwidth for transmitting a data to be transmitted. The data transmitter transmits the data using a second allocated bandwidth allocated to the station based on the required bandwidth.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: The present invention provides a heterocyclic compound represented by General Formula (1): wherein R1 is a group R5—Z1—, etc., Z1 is a lower alkylene group, etc., and R5 is a group represented by General Formula; wherein R13 is a hydrogen atom, etc., m is an integer from 1 to 5; R2 is a hydrogen atom: Y is CH or N: A1 is a heterocyclic ring selected from the group consisting of indolediyl groups, wherein the heterocyclic ring may have at least one substituent: T is a group —CO—, etc.: R3 is a hydrogen atom, etc.: R4 is a lower alkyl group optionally substituted by one or more hydroxy groups, etc.: R3 and R4, together with the nitrogen atom to which they bind, may bind to each other and form a 5- to 10-membered saturated heterocyclic ring, wherein the heterocyclic ring may have at least one substituent. The heterocyclic compound of the present invention has excellent effects of suppressing the production of collagen and/or treating tumors.

Abstract: A control device of a forklift engine that secures operability by keeping down fuel consumption when the accelerator pedal is floored in an unloaded or lightly loaded state, and once a heavy cargo is loaded, by lifting the cargo at a maximum lifting speed and traveling with maximum travel performance without acceleration problems. At least two maximum torque curves of different magnitudes are set in advance on a torque curve diagram. Then, the weight the cargo loaded on an attachment is measured. A threshold value for selecting at least two maximum torque curves is determined. If the measured weight is less than the threshold value, the maximum torque curve with a smaller maximum torque value is selected. If the measured weight is not less than the threshold value, the maximum torque curve with a larger maximum torque value is selected. The engine is controlled using the selected maximum torque curve.

Abstract: A control device of a forklift engine that secures operability by keeping down fuel consumption when the accelerator pedal is floored in an unloaded or lightly loaded state, and once a heavy cargo is loaded, by lifting the cargo at a maximum lifting speed and traveling with maximum travel performance without acceleration problems. At least two maximum torque curves of different magnitudes are set in advance on a torque curve diagram. Then, the weight the cargo loaded on an attachment is measured. A threshold value for selecting at least two maximum torque curves is determined. If the measured weight is less than the threshold value, the maximum torque curve with a smaller maximum torque value is selected. If the measured weight is not less than the threshold value, the maximum torque curve with a larger maximum torque value is selected. The engine is controlled using the selected maximum torque curve.

Abstract: A spreading code generating apparatus carries out M-sequence multiplication and zero value addition of generated orthogonal codes to obtain channel identification codes, and then carries out inverse Fourier transform of the channel identification codes to generate spreading codes and inverse spreading codes. A transmitting apparatus and a receiving apparatus store the spreading codes and the inverse spreading codes generated by the spreading code generating apparatus, respectively, and use a single code respectively selected from the stored codes to carry out spread spectrum communication.

Abstract: Method and apparatus for controlling transmission of a data stream from a station. A QoS registration frame is received, via an access point, from the station. The QoS registration frame includes information indicating a request for transmission of a data stream from the station, and information indicating a minimum required interval and a maximum required interval for an interval which is between start points of two successive durations of a medium dedication. Each duration of the medium dedication represents a time period in which the station is permitted to transmit the data stream. A schedule for the transmission of the data stream is calculated by setting a new interval which is between the minimum required interval and the maximum required interval, when the transmission is admitted.

Abstract: Method and apparatus for controlling transmission of a data stream from a station. A QoS registration frame is received, via an access point, from the station. The QoS registration frame includes information indicating a request for transmission of a data stream from the station, and information indicating a minimum required interval and a maximum required interval for an interval which is between start points of two successive durations of a medium dedication. Each duration of the medium dedication represents a time period in which the station is permitted to transmit the data stream. A schedule for the transmission of the data stream is calculated by setting a new interval which is between the minimum required interval and the maximum required interval, when the transmission is admitted. A QoS response frame, which includes information indicating the schedule, is then transmitted from the access point to the station.

Abstract: A diesel engine includes: a PM filter provided in its exhaust passage; a fuel injection valve for performing post fuel injection in a cylinder of an engine body in addition to primary fuel injection, in order to supply fuel to the PM filter, to maintain its purification performance; an oil level sensor for detecting a degree of dilution of engine oil; and a first indicator lamp that is turned on to indicate that the engine oil needs to be changed when the degree of dilution of engine oil detected by the oil level sensor is equal to or greater than an allowable level. The vehicle diesel engine overrides the prohibition of the post fuel injection until a distance traveled by the vehicle after the indicator lamp is turned on reaches a predetermined distance.